Sanofi to divest its stake in the Yves Rocher Group

Thursday, July 5, 2012 02:21 PM

Global pharmaceutical company Sanofi has divested its direct and indirect stake of approximately 19.3% in the Yves Rocher Group, a company focused on cosmetics, home care products and clothing, to Société Financière des Laboratoires de Cosmétologie Yves Rocher, subject to certain closing conditions.

Upon closing of this transaction, which is expected to take place before the end of the third quarter, the Rocher family will control more than 95% of the Group's capital. The transaction consideration is undisclosed.

Sanofi acquired a stake in the Yves Rocher Group's capital in 1973 and divested part of its stake in the early 2000s.

"We are pleased to have been able to support the development of the Yves Rocher Group for about 40 years,” said Jérôme Contamine, executive vice president and CFO of Sanofi. "The decision to divest is in line with the Group’s objectives to focus on its strategic activities.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs